Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

otsuka pharmaceuticals (u.k. - tolvaptan - tablet - 30mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

otsuka pharmaceuticals (u.k. - tolvaptan - tablet - 15mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

otsuka novel products gmbh - delamanid - tablet - 50mg

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

otsuka pharmaceuticals (u.k. - tolvaptan - tablet - 15mg

Unia Europejska - angielski - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - polycystic kidney, autosomal dominant - diuretics, - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with ckd stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.

Unia Europejska - angielski - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - inappropriate adh syndrome - diuretics, - treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion (siadh).,

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - brexpiprazole (unii: 2j3ybm1k8c) (brexpiprazole - unii:2j3ybm1k8c) - brexpiprazole 0.25 mg - rexulti is indicated for: - adjunctive treatment of major depressive disorder (mdd) in adults - treatment of schizophrenia in adults and pediatric patients ages 13 years and older - treatment of agitation associated with dementia due to alzheimer's disease limitations of use: rexulti is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to alzheimer's disease [see clinical studies (14.3)] . rexulti is contraindicated in patients with a known hypersensitivity to brexpiprazole or any of its components. reactions have included rash, facial swelling, urticaria, and anaphylaxis. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to rexulti during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/ . risk summary adequate and well-controlled studies have not

Australia - angielski - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - cilostazol -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - cilostazol -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; microcrystalline cellulose; hyprolose; colour - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.